London-based Latent Labs has launched what it calls a “frontier AI model” for protein binder design, claiming hit rates of 91-100% for macrocycles and 10-64% for mini-binders across seven therapeutic targets, a dramatic improvement over traditional drug discovery’s sub-1% success rates.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Nick
Contact Nick, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack